Syndax Pharmaceuticals SNDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $64.86M+224% | $68.73M+795% | $45.87M+267% | $37.96M+985% | $20.04M— | ||
| $58.85M-4.5% | $78.64M+20.0% | $56.28M-20.7% | $62.23M+27.9% | $61.64M+9.1% | ||
| —— | $44.92M+48.6% | $44.92M+48.6% | $44.92M+48.6% | $44.92M+48.6% | ||
| $37.59M-8.4% | —— | $44.92M+44.4% | $43.81M+50.7% | $41.03M+78.2% | ||
| $12.05M+16.1% | —— | $12.08M+1.2% | $13.79M+39.3% | $10.38M+16.6% | ||
| $4M— | —— | —— | —— | $0— | ||
| $99.07M-4.6% | $131.28M+26.2% | $103.3M+1.2% | $107.31M+38.1% | $103.8M+30.5% | ||
| $99.07M-4.6% | $131.28M+26.2% | $103.3M+1.2% | $107.31M+38.1% | $103.8M+30.5% | ||
| -$34.2M+59.2% | -$62.55M+35.1% | -$57.43M+35.9% | -$69.35M+6.6% | -$83.76M-5.3% | ||
| -52.7%+365pp | -91%+1,164pp | -125.2%+591pp | -182.7%+1,938pp | -417.9%— | ||
| $0-100% | $0+100% | $0-100% | $4K-91.1% | $2K-96.4% | ||
| $3.56M-50.4% | $4.33M-39.1% | $5.27M-3.2% | $5.95M-5.3% | $7.18M-1.0% | ||
| -$8.47M-678% | -$5.47M-349% | -$3.29M-160% | -$2.49M-141% | -$1.09M-115% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $0— | —— | $0— | $0— | $0— | ||
| -$42.67M+49.7% | -$68.01M+27.8% | -$60.72M+27.8% | -$71.85M-5.6% | -$84.85M-17.2% | ||
| -65.8%+358pp | -99%+1,127pp | -132.4%+541pp | -189.3%+1,755pp | -423.3%— | ||
| -$0.48+51.0% | -$0.78+28.4% | -$0.70+28.6% | -$0.83-3.7% | -$0.98-15.3% | ||
| -$0.48+51.0% | -$0.78+28.4% | -$0.70+28.6% | -$0.83-3.7% | -$0.98-15.3% | ||
| 88.3M+2.4% | 86.6M+1.2% | 86.6M+1.4% | 86.3M+1.2% | 86.2M+1.1% | ||
| 88.3M+2.4% | 86.6M+1.2% | 86.6M+1.4% | 86.3M+1.2% | 86.2M+1.1% | ||
| $0-100% | —— | —— | —— | $247K— | ||
| $11.85M+47.2% | $9.59M+94.6% | $8.28M— | $7.85M— | $8.05M— | ||
| $862K-76.0% | —— | $2.41M-21.1% | $3.21M-12.0% | $3.6M-5.8% | ||
| $12.19M+16.2% | —— | $12.2M+2.3% | $13.9M+40.5% | $10.49M+17.8% | ||
| $12.05M+16.1% | —— | $12.08M+1.2% | $13.79M+39.3% | $10.38M+16.6% | ||
| $56K-50.0% | $0-100% | $62K— | $55K— | $112K— | ||
| -$4.04M-4,386% | —— | —— | -$45.36M-392% | -$90K+100.0% | ||
| $2.63M+198% | $2.71M+228% | $2.1M— | $1.28M— | $885K— | ||
| $0— | —— | $0— | $0— | $0— | ||
| $2.5M+8.7% | —— | $300K-25.0% | $300K-50.0% | $2.3M+53.3% | ||
| $4M— | —— | —— | —— | $0— | ||
| $4K— | —— | $3K+50.0% | $0-100% | $0-100% | ||
| $458K-16.0% | —— | -$80K-115% | $468K+97.5% | $545K+76.4% | ||
| -$5.74M-263% | $2.75M-59.1% | —— | $7.31M+165% | -$1.58M-37.1% | ||
| -$120K-101% | $12.59M+65.7% | $5.95M— | $3.73M— | $8.12M— | ||
| -$6.14M-13,538% | —— | $38K— | —— | -$45K-101% | ||
| -$28.35M-1,019% | $25.7M+120% | $1.1M-94.8% | $17.9M+362% | -$2.53M+62.2% | ||
| $3.24M+146% | —— | -$3.42M— | -$24.5M-451% | -$7.04M-2,336% | ||
| $2.06M-50.8% | $7.8M+2,031% | $7.18M— | $12.92M— | $4.19M— | ||
| -$7.84M-30.8% | $5.4M— | $4.36M-59.1% | $10.77M— | -$5.99M-310% | ||
| $7.92M+751% | $5.92M-98.3% | $6.28M+103% | $551K-18.5% | $930K-57.1% | ||
| $38.39M-59.2% | $81.58M+130% | $72.43M-16.6% | $41.89M— | $94.14M+195% | ||
| -$50.35M+47.1% | -$69.49M-21.1% | -$70.54M-13.2% | -$87.8M-22.5% | -$95.16M-13.9% | ||
| $150M— | —— | —— | —— | —— | ||
| $130K-41.2% | —— | $158K-46.4% | $172K-28.9% | $221K-9.4% | ||
| 1— | —— | —— | —— | —— | ||
| -$43.11M+49.0% | —— | -$60.48M+27.1% | —— | -$84.48M— | ||
| -$441K-221% | —— | $240K-79.8% | -$242K-297% | $364K+137% | ||
| -$186K+15.8% | -$201K-89.6% | -$275K-959% | -$586K-581% | -$221K-154% | ||
| $39.39M+274% | $63.12M-83.2% | $30.44M+128% | $91.71M— | $10.54M-93.7% | ||
| $77.78M-25.7% | $144.75M+34.9% | $103M+2.8% | $133.6M+116% | $104.68M+54.0% | ||
| $7.46M+1,838% | $5.31M+69.2% | $6.36M+148% | $83K-81.1% | $385K-79.3% | ||
| $458K-16.0% | $605K-4.6% | $0-100% | $468K+97.5% | $545K+76.4% | ||
| $64.86M+224% | $68.73M+795% | $45.87M+267% | $37.96M+985% | $20.04M— | ||
| $12.05M+16.1% | $11.25M-8.5% | $12.08M+1.2% | $13.79M+39.3% | $10.38M+16.6% | ||
| $7.46M+1,838% | —— | $6.36M+148% | $83K-81.1% | $385K-79.3% | ||
| -$34.2M+59.2% | -$62.55M+35.1% | -$57.43M+35.9% | -$69.35M+6.6% | -$83.76M-5.3% | ||
| -$30.2M+63.9% | —— | —— | —— | -$83.76M— | ||
| -$30.2M+63.9% | —— | —— | —— | -$83.76M— | ||
| -46.6%+371pp | —— | —— | —— | -417.9%— | ||
| -$34.2M+59.2% | -$62.55M+35.1% | -$57.43M+35.9% | -$69.35M+6.6% | -$83.76M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
